Clinical and biological features of IDH mutation types
| IDH1 R132 . | IDH2 R140 . | IDH2 R172 . |
|---|---|---|
| Equally distributed over ELN2017 risk groups | Most common in the ELN2017 favorable group | Most common in the ELN2017 intermediate group |
| Lower and more spread diagnostic VAF | Diagnostic VAF clustering around 50% | Lower and more spread diagnostic VAF |
| Low clearance rate in remission | ||
| Limited prognostic impact as MRD in transplanted patients with AML | ||
| High NPM1 comutation rate | Low NPM1 comutation rate | |
| Low CD34 surface expression | High CD34 surface expression | |
| High CD33 surface expression | ||
| High CD117 surface expression |
| IDH1 R132 . | IDH2 R140 . | IDH2 R172 . |
|---|---|---|
| Equally distributed over ELN2017 risk groups | Most common in the ELN2017 favorable group | Most common in the ELN2017 intermediate group |
| Lower and more spread diagnostic VAF | Diagnostic VAF clustering around 50% | Lower and more spread diagnostic VAF |
| Low clearance rate in remission | ||
| Limited prognostic impact as MRD in transplanted patients with AML | ||
| High NPM1 comutation rate | Low NPM1 comutation rate | |
| Low CD34 surface expression | High CD34 surface expression | |
| High CD33 surface expression | ||
| High CD117 surface expression |
ELN2017, European LeukemiaNet 2017; MRD, minimal residual disease; VAF, variant allele frequency.